Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Haidmayer, R; Kerbl, R; Meyer, U; Kerschhaggl, P; Kurz, R; Kenner, T.
Effects of naloxone on apnoea duration during sleep in infants at risk for SIDS.
Eur J Pediatr. 1986; 145(5):357-360 Doi: 10.1007/BF00439238
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Führende Autor*innen der Med Uni Graz
Haidmayer Reinhard
Co-Autor*innen der Med Uni Graz
Kenner Thomas
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The effects of intravenous injections of the opiate antagonist naloxone (0.005-0.4 mg/kg body weight) on respiratory pattern, apnoea duration and frequency were investigated in six infants with severe sleep apnoea syndrome. Since several authors found elevated plasma- and CSF-levels of endogenous opioids (endorphines) in infants with sleep apnoea syndrome, we wanted to determine whether the impairment of the control mechanisms of respiration during sleep is due to an effect of endogenous opioids. Independent of the dose, naloxone did not exert any effect on respiratory pattern and occurrence of periodic apnoea. We were unable to prove that endorphines play a major role in pathogenesis of sleep apnoea syndrome in infancy and possibly in sudden infant death syndrome (SIDS). We speculate that elevated levels of endorphines reported by some investigators rather seem to be a consequence of hypoxic stress than a cause for sleep apnoeas.
Find related publications in this database (using NLM MeSH Indexing)
Aminophylline - therapeutic use
Drug Therapy, Combination - therapeutic use
Female - therapeutic use
Humans - therapeutic use
Infant - therapeutic use
Male - therapeutic use
Naloxone - pharmacology
Respiration - drug effects
Risk - drug effects
Sleep - drug effects
Sleep Apnea Syndromes - drug therapy
Sudden Infant Death - etiology

© Med Uni Graz Impressum